<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="Latest Parkinson‚Äôs Disease treatments, including stem cell therapies and inflammation reduction.">
  <title>Latest PD Treatments</title>
  <style>
    body {
      font-family: 'Arial', sans-serif;
      background: #fef6f5;
      margin: 0;
      padding: 10px;
      color: #333;
    }
    .container {
      max-width: 1000px;
      margin: 0 auto;
      background: #fff;
      padding: 10px;
      border-radius: 8px;
      box-shadow: 0 2px 8px rgba(0, 0, 0, 0.1);
    }
    h1 {
      text-align: center;
      color: #EF9280;
      margin-bottom: 10px;
      font-size: 24px;
    }
    .home-button {
      display: block;
      text-align: center;
      margin: 10px auto;
      padding: 6px 12px;
      background: #EF9280;
      color: white;
      border: none;
      border-radius: 5px;
      font-size: 14px;
      cursor: pointer;
      text-decoration: none;
      width: 100px;
    }
    .home-button:hover {
      background: #d87a6b;
    }
    .controls {
      display: flex;
      flex-wrap: wrap;
      gap: 8px;
      margin-bottom: 10px;
      justify-content: center;
    }
    select, input, button {
      padding: 6px;
      border: 1px solid #ddd;
      border-radius: 4px;
      font-size: 13px;
      background: #fff;
      box-sizing: border-box;
    }
    select, button {
      width: 130px;
    }
    input {
      flex: 1;
      min-width: 180px;
      padding-right: 64px;
      border: 1px solid #ccc;
    }
    button {
      border: none;
      cursor: pointer;
      background: #EF9280;
      color: white;
    }
    button:hover {
      background: #d87a6b;
    }
    .search-container {
      position: relative;
      flex: 1;
      /*min-width: 180px;*/
      width: 200px;
    }
    .search-container input {
      width: 100%;
      padding-right: 64px;
      height: 30px;
      box-sizing: border-box;
    }
    .search-container #clearBtn,
    .search-container #searchBtn {
      position: absolute;
      top: 0;
      bottom: 0;
      width: 30px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 14px;
      padding: 0;
    }
    .search-container #clearBtn {
      right: 30px;
      background: transparent;
      color: #333;
      border: none;
      cursor: pointer;
      border-right: 1px solid #ddd;
    }
    .search-container #searchBtn {
      right: 0;
      background: #EF9280;
      border: none;
      border-radius: 0 3px 3px 0;
      color: white;
      cursor: pointer;
    }
    .search-container #searchBtn::before {
      content: 'üîç';
    }
    .search-container #clearBtn:hover {
      background: #f0f0f0;
    }
    .table-wrapper {
      overflow-x: auto;
      -webkit-overflow-scrolling: touch;
    }
    table {
      table-layout: fixed;
      width: 100%;
      border-collapse: collapse;
    }
    td, th {
      white-space: normal;
      word-wrap: break-word;
      vertical-align: top;
      padding: 8px;
      border: 1px solid #ccc;
    }
    th {
      background: #EF9280;
      color: white;
      cursor: pointer;
      white-space: nowrap;
    }
    th:hover {
      background: #d87a6b;
    }
    tr:nth-child(even) {
      background: #fff5f3;
    }
    tr:hover {
      background: #ffe6e2;
    }
    a {
      color: #EF9280;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    th:nth-child(1), td:nth-child(1) { /* Treatment */
      width: 80px;
      overflow: hidden;
      text-overflow: ellipsis;
      white-space: normal;
      word-wrap: break-word;
    }
    th:nth-child(2), td:nth-child(2) { /* Tentative Market Date */
      width: 137px;
      white-space: pre-line; /* Ensure line breaks display */
    }
    th:nth-child(3), td:nth-child(3) { /* Administration */
      width: 108px;
    }
    th:nth-child(4), td:nth-child(4) { /* Goal */
      width: 160px;
      overflow: hidden;
      text-overflow: ellipsis;
      white-space: normal;
      word-wrap: break-word;
    }
    th:nth-child(5), td:nth-child(5) { /* Trial Phase */
      width: 80px;
    }
    th:nth-child(6), td:nth-child(6) { /* Link */
      width: 35px;
    }
    @media (max-width: 600px) {
      th, td {
        font-size: 12px;
        padding: 4px;
      }
      .controls {
        flex-direction: column;
        align-items: stretch;
      }
      select, button {
        width: 100%;
      }
      .search-container {
        min-width: auto;
      }
      .search-container #searchBtn,
      .search-container #clearBtn {
        width: 28px;
      }
      .search-container #clearBtn {
        right: 28px;
      }
      input {
        padding-right: 60px;
      }
    }
  </style>
</head>
<body>
  <div class="container">
    <h1>Snakes & Shields</h1>
    <a href="/" class="home-button">Home</a>
    <div class="controls">
      <div class="search-container">
        <input id="search" type="text" placeholder="Search Treatment...">
        <button id="clearBtn" style="display: none;">‚úï</button>
        <button id="searchBtn"></button>
      </div>
      <select id="sortKey">
        <option value="name">Sort by Treatment</option>
        <option value="tentativeMarketDate">Sort by Tentative Market Date</option>
        <option value="administration">Sort by Administration</option>
        <option value="trialPhase">Sort by Trial Phase</option>
      </select>
      <button id="sortOrder">‚Üì Desc</button>
    </div>
    <div class="table-wrapper">
      <table id="treatmentsTable">
        <thead>
          <tr>
            <th>Treatment</th>
            <th>Tentative Market Date</th>
            <th>Administration</th>
            <th>Goal</th>
            <th>Trial Phase</th>
            <th>Link</th>
          </tr>
        </thead>
        <tbody></tbody>
      </table>
    </div>
  </div>

<script>
const treatments = [
  { id: 87, name: "KM819", administration: "Oral small molecule (LRRK1 inhibitor)", goal: "Reduce alpha-synuclein pathology via LRRK1 inhibition", trialPhase: "Phase 1 completed; Phase 2 planned", link: "https://clinicaltrials.gov/study/NCT03022799", tentativeMarketDate: "2029‚Äì2030" },
  { id: 86, name: "Neuroprosthesis for gait", administration: "Wearable/implantable neurostimulation device", goal: "Restore gait and reduce freezing of gait", trialPhase: "Pilot / early trials", link: "https://clinicaltrials.gov/study/NCT05692714", tentativeMarketDate: "2030+" },
  { id: 85, name: "Ketamine", administration: "Intravenous / intranasal", goal: "Treat depression and possibly improve motor symptoms", trialPhase: "Phase 2 ongoing (depression in PD)", link: "https://clinicaltrials.gov/study/NCT05437254", tentativeMarketDate: "2020s (late)" },
  { id: 84, name: "Psilocybin", administration: "Oral / capsule (psychedelic-assisted therapy)", goal: "Improve mood, reduce depression/anxiety in PD", trialPhase: "Phase 2 planned", link: "https://clinicaltrials.gov/study/NCT04932434", tentativeMarketDate: "2020s (late) ‚Äì 2030s" },
  { id: 83, name: "CPL'36", administration: "Oral small molecule (unknown class)", goal: "Experimental neuroprotection", trialPhase: "Preclinical", link: "https://cpl.org/research", tentativeMarketDate: "Unknown" },
  { id: 82, name: "APL-130277 (Kynmobi)", administration: "Sublingual apomorphine film", goal: "Rapid relief of OFF episodes", trialPhase: "Approved (2020, later withdrawn from market)", link: "https://clinicaltrials.gov/study/NCT02469090", tentativeMarketDate: "Approved (withdrawn)" },
  { id: 81, name: "Vyalev (Produodopa)", administration: "Continuous subcutaneous infusion (levodopa/carbidopa prodrug)", goal: "Reduce motor fluctuations in advanced PD", trialPhase: "Approved in EU (2024)", link: "https://www.ema.europa.eu/en/medicines/human/EPAR/vyalev", tentativeMarketDate: "Marketed (EU)" },
  { id: 80, name: "NLY01", administration: "Subcutaneous injection (GLP-1 receptor agonist)", goal: "Reduce neuroinflammation by blocking microglial activation", trialPhase: "Phase 2 completed (negative)", link: "https://clinicaltrials.gov/study/NCT04154072", tentativeMarketDate: "Unlikely" },
  { id: 79, name: "PR001", administration: "Intracerebral AAV gene therapy", goal: "Deliver GBA1 gene to restore glucocerebrosidase activity", trialPhase: "Phase 1/2 ongoing", link: "https://clinicaltrials.gov/study/NCT04127578", tentativeMarketDate: "2030+" },
  { id: 78, name: "NEU-411", administration: "Oral small molecule (adenosine A2A receptor antagonist)", goal: "Improve motor symptoms and reduce OFF time", trialPhase: "Phase 1 completed; Phase 2 planned", link: "https://clinicaltrials.gov/study/NCT05019879", tentativeMarketDate: "2029‚Äì2030" },
  { id: 77, name: "RO7046015 (UCB0599)", administration: "Oral small molecule", goal: "Inhibit alpha-synuclein misfolding and propagation", trialPhase: "Phase 2 ongoing", link: "https://clinicaltrials.gov/study/NCT04658186", tentativeMarketDate: "2029‚Äì2030" },
  { id: 76, name: "PD01A", administration: "Active immunotherapy (vaccine)", goal: "Induce antibodies against alpha-synuclein", trialPhase: "Phase 1/2 completed", link: "https://clinicaltrials.gov/study/NCT01568099", tentativeMarketDate: "2029‚Äì2030" },
  { id: 75, name: "NPT088", administration: "Intravenous infusion (fusion protein)", goal: "Clear misfolded proteins including alpha-synuclein", trialPhase: "Preclinical / Early clinical", link: "https://www.proclara.com/pipeline", tentativeMarketDate: "2030+" },
  { id: 74, name: "BIIB054 (Cinpanemab)", administration: "Intravenous antibody", goal: "Remove toxic alpha-synuclein aggregates", trialPhase: "Discontinued (Phase 2 negative)", link: "https://clinicaltrials.gov/study/NCT03318523", tentativeMarketDate: "Discontinued" },
  { id: 73, name: "Anle138b", administration: "Oral small molecule", goal: "Inhibit alpha-synuclein aggregation", trialPhase: "Phase 1 completed; Phase 2 planned", link: "https://clinicaltrials.gov/study/NCT04685265", tentativeMarketDate: "2030+" },
  { id: 72, name: "Prasinezumab", administration: "Intravenous infusion (antibody)", goal: "Target and clear aggregated alpha-synuclein", trialPhase: "Phase 2 completed; Phase 2b ongoing", link: "https://clinicaltrials.gov/study/NCT03100149", tentativeMarketDate: "2029‚Äì2030" },
  { id: 71, name: "aDBS", administration: "Adaptive deep brain stimulation", goal: "Optimize DBS by adjusting stimulation in real time", trialPhase: "Clinical trials ongoing", link: "https://clinicaltrials.gov/study/NCT04681534", tentativeMarketDate: "2020s (late)" },
  { id: 70, name: "DBS", administration: "Implanted electrodes in basal ganglia", goal: "Reduce motor symptoms by electrical modulation", trialPhase: "Approved (widely used)", link: "https://clinicaltrials.gov/study/NCT04314819", tentativeMarketDate: "Marketed" },
  { id: 69, name: "GBA1 gene", administration: "Gene therapy / oral modulators", goal: "Target GBA1 mutations or enhance glucocerebrosidase to reduce alpha-synuclein aggregation", trialPhase: "Preclinical / Early clinical", link: "https://clinicaltrials.gov/study/NCT02941822", tentativeMarketDate: "2030+" },
  { id: 7, name: "Dapansutrile", administration: "Oral", goal: "NLRP3 inflammasome inhibition to reduce neuroinflammation in PD", trialPhase: "Phase 2 ongoing", link: "https://clinicaltrials.gov/study/NCT04540120", tentativeMarketDate: "2027‚Äì2028 (pending Phase 3)" },
  { id: 8, name: "Azathioprine", administration: "Oral", goal: "Immunosuppression to slow disease progression in PD", trialPhase: "Phase 2 ongoing", link: "https://clinicaltrials.gov/study/NCT04526686", tentativeMarketDate: "2026‚Äì2027 (pending Phase 3)" },
  { id: 68, name: "NT-0796", administration: "Oral (brain-penetrant NLRP3 inflammasome inhibitor)", goal: "Reduce neuroinflammation and slow PD progression", trialPhase: "Phase 1b/2a completed; further trials planned", link: "https://www.neurologylive.com/view/anti-inflammatory-effects-nt-0796-warrant-future-studies-parkinsons-neurodegeneration", tentativeMarketDate: "2030s (if successful)" },
  { id: 67, name: "SER-252", administration: "Subcutaneous injection (POZ-enabled apomorphine via wearable delivery)", goal: "Provide continuous dopaminergic stimulation to reduce motor fluctuations in advanced PD", trialPhase: "Phase 1b planned; registrational program ahead", link: "https://www.ainvest.com/news/serina-therapeutics-receives-fda-approval-parkinson-trial-shares-rise-hours-2508/", tentativeMarketDate: "2030+ (earliest, pending subsequent trials)" },
  { id: 66, name: "Mannitol", administration: "Oral powder or dissolved in water", goal: "Potentially reduce alpha-synuclein aggregation and provide neuroprotective effects in PD", trialPhase: "Experimental/self-experimentation; small Phase 2 study completed showing safety but no significant efficacy", link: "https://parkinsonsnewstoday.com/news/mannitol-safe-ineffective-parkinsons-symptoms-small-clinical-trial/", tentativeMarketDate: "Not established; human efficacy unproven" },
  { id: 65, name: "ISM8969", administration: "Oral (brain-penetrant small molecule)", goal: "Selective NLRP3 inhibition to reduce neuroinflammation in PD and CNS disorders", trialPhase: "Preclinical (IND submission expected Q4 2025)", link: "https://www.eurekalert.org/news-releases/1094719", tentativeMarketDate: "Early 2030s (pending clinical success)" },
  { id: 64, name: "AAV2-GAD", administration: "Direct brain injection (STN gene therapy)", goal: "Boost GABA production to rebalance motor circuits in PD", trialPhase: "Phase 2 positive; Phase 3 starting 2025", link: "https://clinicaltrials.gov/study/NCT01973543", tentativeMarketDate: "2028‚Äì2029 (pending Phase 3)" },
  { id: 63, name: "Peroneal eTNM¬Æ (URIS I‚Ñ¢ device)", administration: "Home-based (30 min daily, non-invasive neuromodulation)", goal: "Reduce tremor and improve quality of life as an add-on therapy", trialPhase: "Pilot study completed; 24-month follow-up (NCT06570421) ongoing",  link: "https://clinicaltrials.gov/study/NCT06570421", tentativeMarketDate: "2031\nEarly clinical stage, pending larger RCTs." },
  { id: 62, name: "AAV2-GDNF", administration: "Direct brain injection (gene therapy)", goal: "Deliver GDNF to protect and restore dopaminergic neurons", trialPhase: "Phase 1 completed (safety shown, modest clinical benefit)", link: "https://clinicaltrials.gov/study/NCT01621581", tentativeMarketDate: "2030+\nStill experimental; more trials needed before approval." },
  { id: 61, name: "Nilotinib", administration: "Oral", goal: "Potential disease-modifying (modulates Œ±-synuclein aggregation, autophagy)", trialPhase: "Phase II ongoing (PD), Phase IIa completed (DLB)", link: "https://www.michaeljfox.org/grant/phase-iia-safety-and-tolerability-trial-nilotinib-people-parkinsons-disease", tentativeMarketDate: "2029\nDependent on Phase II/III outcomes and regulatory approval"},
  { id: 60, name: "Fetal/Embryonic Stem Cell Grafts", administration: "Cell infusion", goal: "Replace dopamine neurons with fetal/embryonic stem cell-derived neurons", trialPhase: "Historical/limited trials", link: "https://findingdopa.com/science.html", tentativeMarketDate: "Unlikely\nEthical and sourcing challenges limit future use." },
  { id: 59, name: "Propranolol", administration: "Oral (tablet)", goal: "Reduce Parkinsonian tremor via beta-adrenergic blockade", trialPhase: "Repurposed, observational/preclinical", link: "https://findingdopa.com/science.html", tentativeMarketDate: "Unknown\nRepurposed, not in formal PD trials." },
  { id: 58, name: "CREXONT (IPX203)", administration: "Oral (capsule)", goal: "Extended-release carbidopa/levodopa for longer 'on' time", trialPhase: "Phase 3 completed (NCT03877510)", link: "https://clinicaltrials.gov/study/NCT03877510", tentativeMarketDate: "2025\nNDA submitted, market launch expected 2025." },
  { id: 57, name: "Exosome Therapy", administration: "Injection (intranasal/intravenous)", goal: "Deliver neuroprotective factors and alpha-synuclein clearance via engineered exosomes", trialPhase: "Preclinical", link: "https://findingdopa.com/science.html", tentativeMarketDate: "2035\nPreclinical now. Market ~2035 if successful." },
  { id: 56, name: "CRISPR Gene Editing", administration: "Gene editing (in vivo/ex vivo)", goal: "Correct PD-causing mutations (e.g., LRRK2, SNCA) with precision editing", trialPhase: "Preclinical", link: "https://findingdopa.com/science.html", tentativeMarketDate: "2035+\nPreclinical only, years from market." },
  { id: 55, name: "REGENERATE-PD (Gene therapy)", administration: "Intracerebral injection", goal: "Gene therapy to regenerate dopaminergic function and restore motor control", trialPhase: "Preclinical", link: "https://findingdopa.com/science.html", tentativeMarketDate: "2035\nPreclinical, early-stage. Market ~2035 if successful." },
  { id: 54, name: "RNDP-001 (Kenai Therapeutics)", administration: "Cell infusion", goal: "Allogeneic iPSC-derived dopaminergic progenitors for Parkinson‚Äôs treatment", trialPhase: "Preclinical, IND planned", link: "https://kenaitx.com", tentativeMarketDate: "2034\nPreclinical now. Phase 1 ~2026, market ~2034." },
  { id: 53, name: "TFG 001 (TreeFrog Therapeutics)", administration: "Cell infusion", goal: "Scalable iPSC-derived dopaminergic neuron therapy for PD", trialPhase: "Preclinical, Phase 1 planned for 2027", link: "https://treefrog.fr", tentativeMarketDate: "2035\nPreclinical now. Phase 1 ~2027, market ~2035." },
  { id: 52, name: "ICA07 (iCamuno Biotherapeutics)", administration: "Cell infusion", goal: "iPSC-derived dopaminergic precursors to replace lost neurons", trialPhase: "Phase 1 ongoing", link: "https://icamuno.com", tentativeMarketDate: "2032\nPhase 1 ongoing. Market ~2032 if successful." },
  { id: 51, name: "UX-DA001 (Shanghai Yuesai Biotech)", administration: "Cell infusion", goal: "iPSC-derived dopaminergic progenitors for neuronal replacement", trialPhase: "Phase 1 planned (China)", link: "https://yuesai.com", tentativeMarketDate: "2033\nPhase 1 ~2025, Phase 2 ~2027, Phase 3 ~2030, market ~2033." },
  { id: 50, name: "Oryon Cell Therapies (autologous iPSC)", administration: "Cell infusion (autologous)", goal: "Patient-specific iPSC-derived dopaminergic neurons to restore striatal dopamine", trialPhase: "Phase 1 ongoing (Australia)", link: "https://oryoncell.com", tentativeMarketDate: "2032\nPhase 1 ongoing. Market ~2032 if successful." },
  { id: 49, name: "XS-411 (XellSmart Biomedical)", administration: "Cell infusion", goal: "Allogeneic iPSC-derived dopaminergic neuron precursors for Parkinson‚Äôs treatment", trialPhase: "Phase 1 ongoing", link: "https://xellsmart.com", tentativeMarketDate: "2032\nPhase 1 ongoing. Phase 2 ~2026, Phase 3 ~2029, market ~2032." },
  { id: 48, name: "NN-9001 (Novo Nordisk / Lund University)", administration: "Cell infusion", goal: "Stem-cell derived dopaminergic neurons for neuron replacement", trialPhase: "Phase 1 ongoing (NCT05114617)", link: "https://clinicaltrials.gov/study/NCT05114617", tentativeMarketDate: "2031\nPhase 1 ongoing. Phase 3 ~2028, market ~2031." },
  { id: 47, name: "TED-A9 (S. Biomedics)", administration: "Cell infusion", goal: "iPSC-derived dopaminergic progenitors to restore dopamine neurons", trialPhase: "Phase 1/2a ongoing (NCT05565962)", link: "https://clinicaltrials.gov/study/NCT05565962", tentativeMarketDate: "2030\nPhase 1/2a ongoing. Phase 3 ~2027, market ~2030." },
  { id: 46, name: "NouvNeu 001 (iRegene)", administration: "Cell infusion", goal: "Chemically induced iPSC-derived dopaminergic progenitors for neuron replacement", trialPhase: "Phase 1/2 ongoing (NCT06167681)", link: "https://clinicaltrials.gov/study/NCT06167681", tentativeMarketDate: "2031\nPhase 1/2 ongoing. Phase 3 ~2027, market ~2031." },
  { id: 45, name: "CT1-DAP001 (Sumitomo Pharma / CiRA)", administration: "Cell infusion", goal: "Allogeneic iPSC-derived dopaminergic progenitor cells for neuron replacement", trialPhase: "Phase 1/2 ongoing (NCT04651873)", link: "https://clinicaltrials.gov/study/NCT04651873", tentativeMarketDate: "2030\nPhase 1/2 ongoing. Phase 3 ~2027, market ~2030." },
  { id: 44, name: "ANPD001 (Aspen Neuroscience, also called NRG5051)", administration: "Cell infusion (autologous)", goal: "Autologous iPSC-derived dopamine neurons to restore dopaminergic function", trialPhase: "Phase 1/2a ongoing (NCT06381864)", link: "https://clinicaltrials.gov/study/NCT06381864", tentativeMarketDate: "2031\nPhase 1/2a ongoing, market 2031 if successful." },
  { id: 43, name: "Bemdaneprocel (BlueRock Therapeutics)", administration: "Cell infusion", goal: "Replace lost dopamine neurons with iPSC-derived midbrain dopaminergic neurons", trialPhase: "Phase 2 ongoing (NCT04802733)", link: "https://clinicaltrials.gov/study/NCT04802733", tentativeMarketDate: "2030\nPhase 2 ongoing. Phase 3 planned 2027, market 2030." },
  { id: 42, name: "GT-02287", administration: "Oral", goal: "Allosteric activator of glucocerebrosidase (GCase) enzyme to restore activity and reduce alpha-synuclein aggregation", trialPhase: "Phase 1b ongoing", link: "https://clinicaltrials.gov/search?term=GT-02287+Parkinson", tentativeMarketDate: "2030\nPhase 1b ongoing. Positive data in 2025 could initiate Phase 2 in 2026, Phase 3 in 2028, market in 2030." },
  { id: 41, name: "ABL301", administration: "Intravenous (antibody)", goal: "Bispecific antibody targeting aggregated alpha-synuclein and IGF1R for enhanced brain delivery", trialPhase: "Phase 1", link: "https://clinicaltrials.gov/search?term=ABL301+Parkinson", tentativeMarketDate: "2032\nPhase 1 ongoing. Phase 2 expected 2026, Phase 3 in 2028, market in 2032." },
  { id: 40, name: "HER-096", administration: "Subcutaneous injection", goal: "Mimic the effects of cerebral dopamine neurotrophic factor (CDNF) to provide neuroprotection, promote dopamine neuron survival, reduce Œ±-synuclein aggregation and neuroinflammation, to slow or halt Parkinson‚Äôs disease progression", trialPhase: "Phase 1b ongoing (NCT06659562, Parkinson‚Äôs disease patients, 2 doses per week for 4 weeks)", link: "https://clinicaltrials.gov/study/NCT06659562", tentativeMarketDate: "2031\nPhase 1b topline data expected September 2025. Positive results could lead to Phase 2 in 2026, Phase 3 in 2028, potential market entry in 2031 if successful." },
  { id: 39, name: "Buntanetap / Posiphen / ANVS-401", administration: "Oral tablet", goal: "Reduce the production of multiple neurotoxic proteins, including Œ±-synuclein, tau, and amyloid precursor protein, to slow or halt Parkinson‚Äôs disease progression and improve both motor and cognitive symptoms", trialPhase: "Phase 3 completed (NCT05357989, early-stage PD, 10 mg & 20 mg daily dosing)", link: "https://clinicaltrials.gov/study/NCT05357989", tentativeMarketDate: "2027\nPhase 3 completed. NDA planned for 2026, potential approval and market entry in 2027." },
  { id: 38, name: "ENERGI-F705PD", administration: "Oral, sustained-release tablet", goal: "Enhance cellular ATP and antioxidant production, reduce Œ±-synuclein aggregation, boost tyrosine hydroxylase activity for dopamine synthesis", trialPhase: "Phase 1 completed (healthy volunteers, safety/tolerability), preparing for Phase 2", link: "https://www.biospace.com/press-releases/energenesis-biomedical-announces-positive-phase-i-results-for-energi-f705pd-a-potential-disease-modifying-treatment-for-parkinsons-disease", tentativeMarketDate: "2030\nPhase 1 completed. Phase 2 planned 2025, Phase 3 2027, market 2030." },
  { id: 37, name: "VTX3232", administration: "Oral", goal: "NLRP3 inflammasome inhibition to reduce neuroinflammation", trialPhase: "Phase 2a completed, planning Phase 2", link: "https://clinicaltrials.gov/search?term=VTX3232+Parkinson", tentativeMarketDate: "2032\nPhase 2a ongoing, data 2025. Phase 2b 2026, Phase 3 2028, market 2032." },
  { id: 36, name: "UCB0022 (Glovadalen)", administration: "Oral", goal: "Symptom control via D‚ÇÅ receptor positive allosteric modulation", trialPhase: "Phase 1 completed, Phase 2 ongoing (ATLANTIS)", link: "https://clinicaltrials.gov/study/NCT06055985", tentativeMarketDate: "2028\nPhase 2 completed. Phase 3 expected 2025, market 2028." },
  { id: 35, name: "Nicotinamide Riboside (NR, NOPARK)", administration: "Oral", goal: "Disease-modifying (NAD‚Å∫ replenishment, neuroprotection)", trialPhase: "Phase 1 completed, Phase 2/3 ongoing (NOPARK)", link: "https://clinicaltrials.gov/study/NCT03568968", tentativeMarketDate: "2029\nPhase 2 ongoing. Phase 3 2026, market 2029." },
  { id: 34, name: "RB-190 (metyrosine)", administration: "Oral", goal: "Disease-modifying (reduce dopamine-induced neurotoxicity)", trialPhase: "Preclinical, preparing Phase 2 (IND ready)", link: "https://www.prnewswire.com/...RB-190-manufacturing-agreement...", tentativeMarketDate: "2032\nPhase 1 planned. Phase 2 2026, Phase 3 2028, market 2032." },
  { id: 33, name: "Ibuprofen", administration: "Oral", goal: "Neuroprotection potential", trialPhase: "Epidemiology / Preclinical", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unknown\nPreclinical, limited evidence for PD application." },
  { id: 32, name: "Metformin", administration: "Oral", goal: "Mixed data in PD models", trialPhase: "Preclinical / Observational", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unlikely\nMixed preclinical data, no clear path to approval." },
  { id: 31, name: "Rapamycin (Sirolimus)", administration: "Oral", goal: "Autophagy activator", trialPhase: "Preclinical / Early PD studies", link: "https://clinicaltrials.gov/search?term=Rapamycin+Parkinson", tentativeMarketDate: "2032\nPreclinical, early studies. Phase 1/2 2026, Phase 3 2028, market 2032." },
  { id: 30, name: "Empagliflozin", administration: "Oral", goal: "Neuroprotection", trialPhase: "Preclinical", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unknown\nPreclinical, early research." },
  { id: 29, name: "Terazosin", administration: "Oral", goal: "Enhances glycolysis", trialPhase: "Preclinical / Observational", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unknown\nPreclinical, observational data only." },
  { id: 28, name: "Imatinib", administration: "Oral", goal: "LRRK2 modulation, autophagy", trialPhase: "Preclinical", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unknown\nPreclinical, early research." },
  { id: 27, name: "Semaglutide", administration: "Injection (Subcutaneous) or Oral", goal: "Neuroprotection", trialPhase: "Preclinical / Early trials", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "2032\nPreclinical, early trials. Phase 2 2026, Phase 3 2028, market 2032." },
  { id: 26, name: "RB-190 (roscovitine)", administration: "Oral", goal: "LRRK2 kinase inhibition", trialPhase: "Phase 1", link: "https://clinicaltrials.gov/search?term=roscovitine+Parkinson", tentativeMarketDate: "2032\nPhase 1. Phase 2 2026, Phase 3 2028, market 2032." },
  { id: 25, name: "Sunrise-PD (ulotaront)", administration: "Oral", goal: "Non-motor symptoms", trialPhase: "Phase 2", link: "https://clinicaltrials.gov/search?term=ulotaront+Parkinson", tentativeMarketDate: "2029\nPhase 2. Phase 3 2026, market 2029." },
  { id: 24, name: "Lixisenatide", administration: "Injection (Subcutaneous)", goal: "Neuroprotection", trialPhase: "Phase 2", link: "https://clinicaltrials.gov/search?term=Lixisenatide+Parkinson", tentativeMarketDate: "2028\nPhase 2 positive. Phase 3 planned 2025, market 2028." },
  { id: 23, name: "UDCA", administration: "Oral", goal: "Mitochondrial function", trialPhase: "Phase 2/3", link: "https://clinicaltrials.gov/search?term=UDCA+Parkinson", tentativeMarketDate: "2028\nPhase 2 positive. Phase 3 planned 2025, market 2028." },
  { id: 22, name: "Ambroxol", administration: "Oral", goal: "GBA1 enhancer / lysosomal function. Ambroxol is approved as a cough medicine in many countries, but not for PD.", trialPhase: "Phase 3", link: "https://clinicaltrials.gov/search?term=Ambroxol+Parkinson", tentativeMarketDate: "2027\nPhase 3 ongoing. Data 2025, market 2027 if approved." },
  { id: 21, name: "Pioglitazone", administration: "Oral", goal: "Neuroprotection", trialPhase: "Phase 2 completed", link: "https://clinicaltrials.gov/search?term=Pioglitazone+Parkinson", tentativeMarketDate: "Unlikely\nPhase 2 negative, no clear path to approval." },
  { id: 20, name: "BIIB122 (DNL151) ‚Äî LUMA", administration: "Oral (tablet)", goal: "LRRK2 inhibitor aiming to slow progression in early Parkinson‚Äôs disease", trialPhase: "Phase 2b active, not recruiting (NCT05348785)", link: "https://clinicaltrials.gov/study/NCT05348785", tentativeMarketDate: "2029‚Äì2030\nIf Phase 2b is positive, Phase 3 would be required; earliest launch late 2020s." },
  { id: 19, name: "Liraglutide", administration: "Injection (Subcutaneous)", goal: "Neuroprotection", trialPhase: "Phase 2 completed", link: "https://clinicaltrials.gov/search?term=Liraglutide+Parkinson", tentativeMarketDate: "2029\nPhase 2 completed. Phase 3 2026, market 2029." },
  { id: 18, name: "Isradipine", administration: "Oral", goal: "Mitochondrial protection", trialPhase: "Phase 3 completed", link: "https://clinicaltrials.gov/search?term=Isradipine+Parkinson", tentativeMarketDate: "Unlikely\nPhase 3 negative, no clear path to approval." },
  { id: 17, name: "Exenatide", administration: "Injection (Subcutaneous)", goal: "Neuroprotection", trialPhase: "Phase 3", link: "https://clinicaltrials.gov/search?term=Exenatide+PD3", tentativeMarketDate: "Unlikely\nPhase 3 negative, no clear path to approval." },
  { id: 16, name: "Bemnapredocel (cell therapy)", administration: "Cell infusion", goal: "Replace lost dopamine neurons", trialPhase: "Phase 1/2", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "2028\nPhase 1 positive. Phase 3 2025, market 2028." },
  { id: 15, name: "SOD1 modulators", administration: "Injection", goal: "Reduce oxidative stress", trialPhase: "Early research", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unknown\nPreclinical, early research." },
  { id: 14, name: "Alpha-synuclein immunotherapy", administration: "Injection/Infusion", goal: "Remove toxic alpha-synuclein", trialPhase: "Phase 2/3", link: "https://clinicaltrials.gov/search?term=alpha-synuclein+immunotherapy+Parkinson", tentativeMarketDate: "2028\nPhase 2/3 ongoing. Phase 3 2025, market 2028." },
  { id: 13, name: "Apomorphine (Onapgo, Apokyn)", administration: "Oral film, sublingual", goal: "Reduce 'off' episodes", trialPhase: "Approved", link: "https://clinicaltrials.gov/search?term=Apomorphine+Parkinson", tentativeMarketDate: "Marketed" },
  { id: 12, name: "Copper supplements", administration: "Oral (tablet)", goal: "Restore copper balance, antioxidant effect", trialPhase: "Early research", link: "https://findingdopa.com/clinical-trials.html", tentativeMarketDate: "Unknown\nPreclinical, early research." },
  { id: 10, name: "NE3107 (Bezisterim)", administration: "Oral (tablet)", goal: "Reduce neuroinflammation, early therapy", trialPhase: "Phase 2", link: "https://clinicaltrials.gov/search?term=NE3107", tentativeMarketDate: "2029\nPhase 2 ongoing. Phase 3 2026, market 2029." },
  { id: 9, name: "GZ/SAR402671 (Venglustat)", administration: "Oral (tablet)", goal: "Target GBA mutation, slow progression", trialPhase: "Phase 2", link: "https://clinicaltrials.gov/search?term=Venglustat", tentativeMarketDate: "Discontinued\nPhase 2 negative, no further development." },
  { id: 6, name: "Tavapadon", administration: "Oral (tablet)", goal: "D1/D5 partial agonist, motor symptom control", trialPhase: "Phase 3", link: "https://clinicaltrials.gov/search?term=Tavapadon", tentativeMarketDate: "2025\nPhase 3 positive. Launch 2025." },
  { id: 5, name: "LRRK2 inhibitors (DNL151/BIIB122)", administration: "Oral (tablet)", goal: "Slow progression in LRRK2 mutation carriers", trialPhase: "Phase 3", link: "https://clinicaltrials.gov/search?term=DNL151+Parkinson", tentativeMarketDate: "2028\nPhase 2/3 ongoing. Phase 3 data 2025, market 2028." },
  { id: 4, name: "AL-101 (intranasal apomorphine)", administration: "Intranasal spray (dopamine agonist)", goal: "Rapid relief of OFF episodes in PD; also studied for sexual dysfunctions", trialPhase: "Phase 2 ongoing", link: "[https://clinicaltrials.gov/study/NCT05258071](https://clinicaltrials.gov/study/NCT05258071)", tentativeMarketDate: "2027‚Äì2028 (if Phase 3 successful)" },
  { id: 3, name: "Celeste¬Æ (PhotoPharmics)", administration: "At-home evening phototherapy (‚âà1 hr/day)", goal: "Non-drug light therapy to improve motor & non-motor PD symptoms via retinal/circadian pathways", trialPhase: "Pivotal randomized trial (FDA Breakthrough) ongoing", link: "https://www.lightforpd.com", tentativeMarketDate: "2026 (pending FDA review)" },
  { id: 2, name: "Extended-release Levodopa/Carbidopa", administration: "Oral (tablet/capsule)", goal: "Reduce 'off' time, improved symptom control", trialPhase: "Approved", link: "https://clinicaltrials.gov/study/NCT05036473", tentativeMarketDate: "Marketed" },
  { id: 1, name: "Levodopa/Carbidopa", administration: "Oral (tablet/capsule)", goal: "Symptom control (dopamine replacement)", trialPhase: "Approved", link: "https://clinicaltrials.gov/study/NCT05036473", tentativeMarketDate: "Marketed" }
];

// DOM elements
const searchInput = document.getElementById('search');
const searchBtn = document.getElementById('searchBtn');
const clearBtn = document.getElementById('clearBtn');
const sortKey = document.getElementById('sortKey');
const sortOrderBtn = document.getElementById('sortOrder');
const tableBody = document.getElementById('treatmentsTable').querySelector('tbody');

// State
let currentSortKey = 'name';
let currentSortOrder = 'asc';
let currentSearch = '';

// Helper: Parse market date for sorting
function parseMarketDate(val) {
  if (!val) return Infinity;

  // Extract the first line (before \n)
  const firstLine = val.split('\n')[0].trim();

  // Handle special cases
  if (firstLine === "Marketed") return -Infinity; // Sort first
  if (firstLine === "Unlikely" || firstLine === "Unknown" || firstLine === "Discontinued") return Infinity; // Sort last

  // Parse numeric year (e.g., "2027")
  const year = parseInt(firstLine, 10);
  if (!isNaN(year)) return year;

  // Fallback for any unexpected format
  return Infinity;
}

// Render table
function renderTable() {
  let filtered = treatments.filter(t =>
    t.name.toLowerCase().includes(currentSearch.toLowerCase())
  );

  filtered.sort((a, b) => {
    if (currentSortKey === 'tentativeMarketDate') {
      const aDate = parseMarketDate(a.tentativeMarketDate);
      const bDate = parseMarketDate(b.tentativeMarketDate);
      return currentSortOrder === 'desc' ? bDate - aDate : aDate - bDate;
    }
    // All others compared as strings (case-insensitive)
    return currentSortOrder === 'desc'
      ? String(b[currentSortKey]).localeCompare(String(a[currentSortKey]))
      : String(a[currentSortKey]).localeCompare(String(b[currentSortKey]));
  });

  tableBody.innerHTML = '';
  filtered.forEach(t => {
    const row = document.createElement('tr');
    row.innerHTML = `
      <td>${t.name}</td>
      <td>${t.tentativeMarketDate}</td>
      <td>${t.administration}</td>
      <td>${t.goal}</td>
      <td>${t.trialPhase}</td>
      <td><a href="${t.link}" target="_blank">Link</a></td>
    `;
    tableBody.appendChild(row);
  });

  // Keep sort button label in sync after each render
  sortOrderBtn.textContent = currentSortOrder === 'desc' ? '‚Üì Desc' : '‚Üë Asc';
}

function updateSearch() {
  currentSearch = searchInput.value;
  clearBtn.style.display = searchInput.value ? 'flex' : 'none';
  renderTable();
}

searchInput.addEventListener('input', updateSearch);
searchBtn.addEventListener('click', updateSearch);

clearBtn.addEventListener('click', () => {
  searchInput.value = '';
  currentSearch = '';
  clearBtn.style.display = 'none';
  renderTable();
});

sortKey.addEventListener('change', e => {
  currentSortKey = e.target.value;
  renderTable();
});

// Sort order button toggles direction
sortOrderBtn.addEventListener('click', () => {
  currentSortOrder = currentSortOrder === 'desc' ? 'asc' : 'desc';
  renderTable();
});

// Initial: Sync button text and render
sortOrderBtn.textContent = currentSortOrder === 'desc' ? '‚Üì Desc' : '‚Üë Asc';
renderTable();
</script>
</body>
</html>
